Answers are grounded in this paper and cite their sources.
INTRODUCTION: To evaluate the efficacy of SB5, an adalimumab biosimilar, in the management of Behçet's syndrome (BS)-related uveitis. METHODS: Data from eight BS patients (16 eyes) with active non-anterior uveitis and/or systemic uncontrolled disease or performing non-medical switch to SB5 were retrospectively collected and analyzed. RESULTS: Complete control of uveitis was observed in all 16 eyes without relapses during follow-up. The number of relapses 12 months prior to SB5 initiation and at last follow-up was 100 and 0 per 100 patients/year, respectively (p = 0.010). At baseline, four eyes had active retinal vasculitis, whereas at 3 months and at last follow-up, retinal vasculitis had resolved in all of them (p = 0.018). Median visual acuity did not vary significantly between baseline and last follow-up visit (p = 0.109). No ocular complications emerged during treatment. CONCLUSIONS: SB5 is effective in the treatment of BS-related non-anterior uveitis. It reduces uveitis relapses and controls retinal vasculitis while allowing preservation of visual acuity.
No takes yet. Share an insight, caveat, or question.
Sota et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: